182317-41-5

Upstream product

• 932-31-0 ortho-tolylmagnesium bromide 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 3153-37-5 methyl 4-chlorobutyrate 
• 95-46-5 2-methylphenyl bromide 
• 141-78-6 ethyl acetate 

Downstream Products

• 193898-05-4 4,4-Di-o-tolyl-but-3-en-1-ol 
• 182317-46-0 4,4-di(2-tolyl)-3-butenyl iodide 
• 182317-61-9 4,4-di(2-tolyl)-1-butanol 
• 193898-15-6 1-(4,4-Di-o-tolyl-butyl)-4-phenyl-1,4-dihydro-pyridine-3-carboxylic acid 2-cyano-ethyl ester 
• 193898-16-7 1-(4,4-Di-o-tolyl-but-3-enyl)-4-phenyl-1,4-dihydro-pyridine-3-carboxylic acid 2-cyano-ethyl ester 
• 193898-23-6 1-(4,4-Di-o-tolyl-butyl)-6-phenyl-1,6-dihydro-pyridine-3-carboxylic acid 2-cyano-ethyl ester 
• 193898-25-8 1-(4,4-Di-o-tolyl-but-3-enyl)-6-phenyl-1,6-dihydro-pyridine-3-carboxylic acid 2-cyano-ethyl ester 
• 193898-02-1 Toluene-4-sulfonic acid 4,4-di-o-tolyl-butyl ester 
• 193898-06-5 Toluene-4-sulfonic acid 4,4-di-o-tolyl-but-3-enyl ester 
• 193898-03-2 1,1-bis(2-methylphenyl)-4-bromobutane 

Relevant academic research and scientific papers

Selective inhibitors of GABA uptake: Synthesis and molecular pharmacology of 4-N-methylamino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol analogues

A series of lipophilic diaromatic derivatives of the glia-selective GABA uptake inhibitor (R)-4-amino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol [(R)-exo-THPO, 4] were synthesized via reductive amination of 3-ethoxy-4,5,6,7-tetrahydrobenzo[d]isoxazol-4-one (9) or via N-alkylation of O-alkylatedracemic 4. The effects of the target compounds on GABA uptake mechanisms in vitro were measured using a rat brain synaptosomal preparation or primary cultures of mouse cortical neurons and glia cells (astrocytes), as well as HEK cells transfected with cloned mouse GABA transporter subtypes (GAT1-4). The activity against isoniazid-induced convulsions in mice after subcutaneous administration of the compounds was determined. All of the compounds were potent inhibitors of synaptosomal uptake the most potent compound being (RS)-4-[N-(1,1-diphenylbut-1-en-4-yl)amino]-4,5,6,7-tetrahydrobenzo[d] isoxazol-3-ol (17a, IC50 = 0.14 μM). The majority of the compounds showed a weak preference for glial, as compared to neuronal, GABA uptake. The highest degree of selectivity was 10-fold corresponding to the glia selectivity of (R)-N-methyl-exo-THPO (5). All derivatives showed a preference for the GAT1 transporter, as compared with GAT2-4, with the exception of (RS)-4-[N-[1,1- bis(3-methyl-2-thienyl)but-1-en-4-yl]-N-methylamino]-4,5,6,7-tetrahydrobenzo[d] isoxazol-3-ol (28d), which quite surprisingly turned out to be more potent than GABA at both GAT1 and GAT2 subtypes. The GAT1 activity was shown to reside in (R)-28d whereas (R)-28d and (S)-28d contributed equally to GAT2 activity. This makes (S)-28d a GAT2 selective compound, and (R)-28d equally effective in inhibition of GAT1 and GAT2 mediated GABA transport. All compounds tested were effective as anticonvulsant reflecting that these compounds have blood-brain barrier permeating ability.

4-aminotetrahydrobenzisoxazole or -isothiazole compounds

The present invention relates to novel 4-aminotetrahydrobenzisoxazoles or 4-aminotetrahydrobenziothiazoles having gamma-aminobutanoic acid (GABA)-uptake inhibiting activity and thus useful in the treatment of analgesia, psychosis, convulsions, anxiety, epileptic disorders or muscular and movement disorders, such as spastic disorders or symptoms in Huntington's disease or Parkinson disease.

Synthesis of 4,4-bis(2-methylphenyl)-3-butenyl (and butyl) analogs of 4-phenyl-1,4- and 6-phenyl-1,6-dihydropyridine-3-carboxylic acids and their evaluation as neuronal GABA-uptake inhibitors

Treatment of 3-[2-(4,4-dimethyl-4,5-dihydrooxazolin-2-yl)]-4-phenyl-1,4-dihydropyridine (13) with NaH-DMSO, and then reaction with 1,1-bis(2-methylphenyl)-4-bromobutane (12c) afforded 1-[4,4-bis(2-methylphenyl)butyl]-3-[2-(4,4-dimethyl-4,5-dihydrooxazolin-2-yl)]- 4-phenyl-1,4-dihydropyridine (14). Reaction of methyl nicotinate with 2.1 equivalents 12c or 1,1-bis(2-methylphenyl)-4-bromo-1-butene (11b) afforded 4,4-bis(2-methylphenyl)butyl 1-[4,4-bis(2-methylphenyl)butyl]pyridinium-3-carboxylate bromide (17) or 4,4-bis(2-methylphenyl)-3-butenyl 1-[4,4-bis(2-methylphenyl)-3-butenyl]pyridinium-3-carboxylate bromide (18), respectively. The nonregioselective reaction of the pyridinium salts (17/18) with PhMgCl in THF at -23°C using a catalytic amount of CuI afforded a mixture of isomeric 4-phenyl-1,4-dihydropyridyl (21 or 22) and 6-phenyl-1,6-dihydropyridyl (27 or 28) products in a ratio of approximately 1:1. All attempts to hydrolyze the 4,4-bis(2-methylphenyl)butyl or 3-butenyl ester moiety of 21/22 or 27/28 to a carboxyl group resulted in decomposition products. In contrast, the corresponding 3-(2-cyanoethyl) esters (23, 24, 29, 30) were readily converted to the corresponding carboxyl analogs (25, 26, 31, 32) via a β-elimination reaction of acrylonitrile using the non-nucleophilic base DBU. The 4-phenyl-1,4-dihydropyridyl (14, 25, 26) and 6-phenyl-1,6-dihydropyridyl (27/28 or 31/32) compounds inhibited the in vitro uptake of [3H]GABA into striatal prisms in the 21-44% range at a 10-4 M test compound concentration, relative to the reference drug nipecotic acid (87% inhibition). Structure-activity correlations showed the dihydropyridyl C-3 substituent was a determinant of [3H]GABA uptake where the potency order was CO2H > 2-(4,4-dimethyl-4,5-dmydrooxazolin-2-yl) > CO2(CH2)3CH-(o-tolyl)2 and CO2(CH2)2CH=C-(o-tolyl)2. Compounds possessing C-3 and (or) N-1 CO2(CH2)3CH-(o-tolyl)2 substituents were generally more potent than analogs having CO2(CH2)2CH=C-(o-tolyl)2 substituents. In general, 1,6-dihydropyridyl compounds were more potent than the corresponding 1,4-dihydropyridyl isomers.